GPCRStructure Therapeutics
About Structure Therapeutics
Structure Therapeutics (NASDAQ:GPCR) is a biopharmaceutical company focused on designing and developing novel therapies aimed at treating chronic metabolic diseases. At the heart of their operations is a platform technology that leverages structural biology to discover and optimize therapeutics that can modulate G protein-coupled receptors (GPCRs), a large family of proteins that play a crucial role in various physiological processes. Their projects primarily focus on addressing unmet needs in obesity, diabetes, and other metabolic disorders, aiming to bring forth innovative treatment options for patients worldwide. Structure Therapeutics is committed to pushing the boundaries of drug discovery, aiming to enhance patient health and quality of life through their scientific and clinical advancements.
What is GPCR known for?
Snapshot
Public US
Ownership
2016
Year founded
91
Employees
South San Francisco, United States
Head office
1 of 4
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...
Operations
All Locations
South San Francisco, US
Products and/or services of Structure Therapeutics
- Development of oral small molecule GLP-1 receptor agonists for the treatment of type 2 diabetes and obesity, targeting a core need in metabolic disorder treatments.
- Advancement of oral small molecule CGRP receptor antagonists, aimed at preventing migraine, addressing the growing need for effective migraine management solutions.
- Proprietary platform for structure-based drug discovery, enabling the rapid and efficient identification of novel therapeutics targeting G protein-coupled receptors (GPCRs).
- Research into oral small molecule GIP receptor agonists, exploring their potential in improving outcomes for patients with metabolic diseases.
- Development of dual agonists targeting both GLP-1 and GIP receptors, seeking to offer superior treatment options for diabetes and obesity.
- Custom drug discovery services, leveraging their structural biology expertise to aid in the development of GPCR-targeting drugs for external partners.
Structure Therapeutics executive team
- Dr. Raymond C. Stevens Ph.D.CEO & Director
- Dr. Xichen Lin Ph.D.Chief Scientific Officer & GM of Structure Shanghai
- Dr. Blai Coll M.D., Ph.D.Chief Medical Officer
- Mr. Jun S. YoonCo- Founder, CFO & Secretary
- Dr. Yingli Ma Ph.D.Chief Technology Officer
- Mr. Tony PengSenior Vice President of Legal
- Mr. Bob GatmaitanSenior Vice President of People
- Dr. Hui Lei Ph.D.Senior Vice President of Chemistry
- Dr. Fang Zhang Ph.D.Executive VP & Head of Biology
- Ms. Lani IbarraSenior Vice President of Clinical Development Operations